Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
Nicholas Kim Huat Khoo, Joey Ming Er Lim, Upkar S. Gill, et al.
Med (2022) Vol. 3, Iss. 2, pp. 104-118.e4
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
Alison Tarke, Camila H. Coelho, Zeli Zhang, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 847-859.e11
Open Access | Times Cited: 760
Humoral and cellular immune memory to four COVID-19 vaccines
Zeli Zhang, José Mateus, Camila H. Coelho, et al.
Cell (2022) Vol. 185, Iss. 14, pp. 2434-2451.e17
Open Access | Times Cited: 444
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Alessandro Sette, Shane Crotty
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 27-46
Open Access | Times Cited: 214
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
T Cell Responses to SARS-CoV-2
Alessandro Sette, John Sidney, Shane Crotty
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 343-373
Closed Access | Times Cited: 114
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
Antonio Bertoletti, Nina Le Bert, Anthony T. Tan
Immunity (2022) Vol. 55, Iss. 10, pp. 1764-1778
Open Access | Times Cited: 92
Heterologous prime–boost strategies for COVID-19 vaccines
Binaya Sapkota, Bhuvan Saud, Ranish Shrestha, et al.
Journal of Travel Medicine (2021)
Open Access | Times Cited: 81
A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines
Joey Ming Er Lim, Shou Kit Hang, Smrithi Hariharaputran, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100793-100793
Open Access | Times Cited: 54
Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection
Behnam Keshavarz, Nathan E. Richards, Lisa J. Workman, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1822-1849
Open Access | Times Cited: 44
Humoral and cellular immune memory to four COVID-19 vaccines
Zeli Zhang, José Mateus, Camila H. Coelho, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 41
Impact of SARS-CoV-2 exposure history on the T cell and IgG response
Roanne Keeton, Marius B. Tincho, Akiko Suzuki, et al.
Cell Reports Medicine (2022) Vol. 4, Iss. 1, pp. 100898-100898
Open Access | Times Cited: 41
Defending against SARS-CoV-2: The T cell perspective
Patricia Almendro-Vázquez, Rocío Laguna‐Goya, Estela Paz‐Artal
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 36
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Dennis Lapuente, Thomas Winkler, Matthias Tenbusch
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 144-158
Open Access | Times Cited: 29
A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines
Feargal J. Ryan, Todd S. Norton, Conor McCafferty, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 3, pp. 100971-100971
Open Access | Times Cited: 25
Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
Xiaogang Tong, R. P. McNamara, María José Avendaño, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Virus-specific T cell response in SARS-CoV-2 infection and vaccinations
Antonio Bertoletti, Martin Qui, Joey Ming Er Lim
Elsevier eBooks (2025), pp. 191-206
Closed Access
Favorable vaccine-induced SARS-CoV-2–specific T cell response profile in patients undergoing immune-modifying therapies
Martin Qui, Nina Le Bert, Webber Chan, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 12
Open Access | Times Cited: 26
Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020–2023): a multicentre prospective cohort study
Anis Karuniawati, Ayodhia Pitaloka Pasaribu, L Gilbert, et al.
The Lancet Regional Health - Southeast Asia (2024) Vol. 22, pp. 100348-100348
Open Access | Times Cited: 4
The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine
Eman Farid, Júber Herrera-Uribe, Nigel J. Stevenson
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 19
Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2
Emanuel Vogel, Katharina Kocher, Alina Priller, et al.
EBioMedicine (2022) Vol. 85, pp. 104294-104294
Open Access | Times Cited: 18
Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles
Emma Touizer, Aljawharah Alrubayyi, Rosemarie Ford, et al.
iScience (2022) Vol. 26, Iss. 1, pp. 105862-105862
Open Access | Times Cited: 18
Real-world data on the incidence and risk of Guillain–Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study
Jongmok Ha, Suyeon Park, Hyunwook Kang, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
Catherine Riou, Jinal N. Bhiman, Yashica Ganga, et al.
PLOS Global Public Health (2024) Vol. 4, Iss. 4, pp. e0002703-e0002703
Open Access | Times Cited: 3
Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period—United States, 1 January 2022 to 31 March 2022
Lyudmyla Kompaniyets, Ryan E. Wiegand, Adewole C Oyalowo, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 10, pp. 1753-1760
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top